Novo Nordisk, Minnesota Settle to Resolve Insulin Price Case (1)

Novo Nordisk A/S on Monday became the final insulin manufacturer to reach a proposed settlement agreement with Minnesota, tentatively ending a seven-year lawsuit over the affordability of the diabetes medication.

The agreement, which is subject to the approval of the US District Court for the District of New Jersey, states that Novo Nordisk has agreed to cap the price of its insulin products at $35 per month for all Minnesotans, with or without insurance, for at least five years.

The settlement is similar to agreements Minnesota Attorney General Keith Ellison (D) secured in 2024 with Eli Lilly & Co. ...